FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to therapeutic fused proteins. Disclosed is a fused protein with SEQ ID NO: 34, 73 or 147, comprising an integrin-binding domain, a phosphatidylserine (PS)-binding domain and a solubilising domain. Invention provides production of fused proteins based on structure of naturally occurring bridge proteins, namely MFG-E8, which preserve the basic biological functions of the wild-type protein - function to ensure the binding of PS-representing dying cells, debris and microparticles with phagocytes and thus provide triggering of eferocytosis, while characterized by reduced stickiness and improved solubility, longer exposure time in blood plasma and higher output when expressed in cell expression systems compared to wild-type MFG-E8 protein with SEQ ID NO: 1, and also have stability compared to truncated by C2 MFG-E8 and increased solubility compared to wild type at least 50 times.
EFFECT: invention can be used in medicine for intensifying eferocytosis and in treating inflammation associated with reduced eferocytosis.
3 cl, 23 dwg, 10 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC FUSION PROTEINS | 2020 |
|
RU2825292C1 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2698655C2 |
| FUSED SERPINE POLYPEPTIDES AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2746550C2 |
| POLYPEPTIDES THAT BIND TO THE C5 COMPONENT OR TO SERUM ALBUMIN AND THEIR FUSION PROTEINS | 2018 |
|
RU2794359C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| NUCLEOTIDE SEQUENCE ENCODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN Dll4 AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IgG4 | 2021 |
|
RU2787060C1 |
| ANTIBODIES CONTAINING POLYPEPTIDE INTEGRATED INTO FRAME REGION 3 | 2019 |
|
RU2796254C2 |
| FUSED PROTEINS WITH ALBUMIN-BINDING DOMAINS | 2018 |
|
RU2786444C2 |
| TGFβR2 MOLECULE WITH TRUNCATED EXTRACELLULAR DOMAIN, FUSION PROTEIN OF TGFβR2 MOLECULE WITH TRUNCATED EXTRACELLULAR DOMAIN, AND ANTI-EGFR ANTIBODIES, AND ANTI-TUMOUR USE OF FUSED PROTEIN | 2021 |
|
RU2824199C1 |
